Clarity Pharmaceuticals
Clarity Pharmaceuticals is a clinical-stage company specializing in radiopharmaceuticals, focusing on theranostic products that combine therapy and imaging. Utilizing its proprietary SAR Technology, Clarity aims to improve cancer treatment outcomes with its Targeted Copper Theranostic platform. The company is positioned as a leader in next-generation radiopharmaceuticals, offering products that provide high accuracy and precision in cancer treatment.
Short position
Clarity Pharmaceuticals (ASX:CU6) has 8.94% of its shares on issue reported as short positions as of 5 Oct 2026, or about 33,345,512 shares. Over the past 30 days that figure has risen 0.39 percentage points, and over 90 days it has risen 1.63 percentage points. Its highest recorded short interest was 10.24% in July 2025. CU6 is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4CU6 community
Research Threads
Bull, bear, catalyst, and news-reaction posts tied directly to CU6.
Start the first CU6 research thread
Anchor the conversation with a thesis, a catalyst, or a question worth debating.